Ritonavir/salmeterol/fluticasone propionate interactionHypercortisolism: 2 case reports

被引:0
作者
机构
关键词
Chronic Obstructive Pulmonary Disease; Ritonavir; Fluticasone; Urinary Free Cortisol; Cushing Syndrome;
D O I
10.2165/00128415-201214040-00114
中图分类号
学科分类号
摘要
引用
收藏
页码:34 / 34
相关论文
共 50 条
[31]   Efficacy and Safety Analysis of Salmeterol/Fluticasone Propionate with Tiotropium Bromide for Chronic Obstructive Pulmonary Disease [J].
Zhang, Zili .
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 86 :128-133
[34]   Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization [J].
Ainali, Nina Maria ;
Xanthopoulou, Eleftheria ;
Michailidou, Georgia ;
Zamboulis, Alexandra ;
Bikiaris, Dimitrios N. .
MOLECULES, 2020, 25 (17)
[38]   The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide [J].
Wedzicha, Jadwiga A. ;
Calverley, Peter M. A. ;
Seemungal, Terence A. ;
Hagan, Gerry ;
Ansari, Zainab ;
Stockley, Robert A. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (01) :19-26
[40]   Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice [J].
Soriano, JB ;
Vestbo, J ;
Pride, NB ;
Kiri, V ;
Maden, C ;
Maier, WC .
EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (04) :819-825